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Available online 9 January 2018 Acute myocardial infarction (AMI) and the heart failure that often follows, are major causes of death and
disability worldwide. As such, new therapies are required to limit myocardial infarct (MI) size, prevent adverse
left ventricular (LV) remodeling, and reduce the onset of heart failure following AMI. The inﬂammatory response
to AMI, plays a critical role in determining MI size, and a persistent pro-inﬂammatory reaction can contribute to
adverse post-MI LV remodeling, making inﬂammation an important therapeutic target for improving outcomes
following AMI. In this article, we provide an overview of the multiple players (and their dynamic roles) involved
in the complex inﬂammatory response to AMI and subsequent LV remodeling, and highlight future opportunities
for targeting inﬂammation as a therapeutic strategy for limiting MI size, preventing adverse LV remodeling, and
reducing heart failure in AMI patients.
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